Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug KESONOTIDE™ enters human trials for multiple cancers

NCT ID NCT06926075

First seen Oct 01, 2025 · Last updated May 23, 2026 · Updated 23 times

Summary

This study tests a new experimental drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, pancreatic, skin cancer, or glioblastoma. The main goal is to check the drug's safety and find the right dose. About 80 adults will take part in two phases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • South Western Sydney Local Health District

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Southside Cancer Centre

    RECRUITING

    Miranda, New South Wales, 2228, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • St George Private Hospital

    RECRUITING

    Kogarah, New South Wales, 2217, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.